ClinicalTrials.gg
CompletedNCT01783548Updated Oct 12, 2015Results posted

Study of an Investigational Nasal Aerosol or Placebo in Children (Ages 4 to 11) With Perennial Allergic Rhinitis (PAR)

A Phase 3 interventional study of BDP Nasal Aerosol and Placebo in Allergic Rhinitis, sponsored by Teva Branded Pharmaceutical Products R&D, Inc.. Completed at 63 sites in United States. Open to participants aged 4 Years to 11 Years. Per ClinicalTrials.gov, last updated 2015-10-12.

Sponsored by Teva Branded Pharmaceutical Products R&D, Inc. (part of Teva Pharmaceutical Industries, Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
547
Allocation
Randomized
Ages
4 Years to 11 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 141 studies in Rhinitis, Allergic with a site in United States — 5 open to participants now, 7 under way, none of them phase 3. Rhinitis, Allergic · United States.

Enrollment
18th of 119
547 · median 54
Started
2013
with 7 others
Phase 3
33 of 141
none open now
Registered
95th of 141
by date

Among the 141 studies in Rhinitis, Allergic with a site in United States, this one is the 18th largest by enrollment of the 119 interventional ones that give a count, is one of 8 that started in 2013, is one of 33 in phase 3, and was the 95th registered.

Rhinitis, Allergic

717 studies on the registry are indexed under Rhinitis, Allergic; 94 are open to participants now.

Browse Rhinitis, Allergic studies →

Open to participants now

5 of the 141 studies in Rhinitis, Allergic with a site in United States are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 54 Rhinitis, Allergic studies recruiting now, 11 (20%) set no upper age limit and 38 (70%) stop at 75 or younger; 22 take children under 18; 13 take healthy volunteers.

This study: 4 Years to 11 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 141 studies in Rhinitis, Allergic with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of Beclomethasone dipropionate (BDP) nasal aerosol in subjects with Perennial Allergic Rhinitis (PAR).

03

Conditions studied

  • Allergic Rhinitis

Browse trials for

Keywords

  • allergic rhinitis
  • pediatric subjects
  • BDP nasal aerosol
04

Who can participate

Ages eligible
4 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects 4 to 11 years of age, inclusive, as of the Screening Visit (SV).
  • A documented history of PAR to a relevant perennial allergen for a minimum of 12 months (6 months for subjects 4 to 5 years of age) immediately preceding the study Screening Visit (SV).
  • A demonstrated sensitivity to at least one allergen known to induce PAR through a standard skin prick test.
  • Other criteria apply.

Exclusion criteria

Exclusion Criteria:

  • History of physical findings of nasal pathology, including nasal polyps or other respiratory tract malformations, recent nasal , nasal trauma (e.g., nasal piercing) or surgery, atrophic rhinitis, or rhinitis medicamentosa (all within the last 60 days prior to the Screening Visit [SV]).
  • History of a respiratory infection or disorder (including, but not limited to bronchitis, pneumonia, chronic sinusitis or influenza) within the 14 days preceding the Screening Visit (SV), or development of a respiratory infection during the Run-In Period.
  • Active asthma requiring treatment with inhaled or systemic and/or routine use of beta-agonists and any controller drug (e.g., theophylline, leukotriene antagonists). History of intermittent use (less than or equal to 3 uses per week) of inhaled short acting beta-agonists prior to the Screening Visit (SV) is acceptable.
  • Have any of the following conditions that are judged by the investigator to be clinically significant and/or affect the subject's ability to participate in the clinical trial.
  • Other criteria apply.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
547 participants (actual)

Study arms

  • Experimental
    BDP Nasal Aerosol 80 mcg/day

    BDP nasal aerosol: 80 mcg dose once daily in the morning. Participants/parents administer 40 mcg BDP (one spray per nostril) during the 12-week Treatment Period.

    Drug: BDP Nasal Aerosol

  • Placebo comparator
    Placebo Nasal Aerosol

    Placebo nasal aerosol: Participants/parents administer placebo (no medication) (one spray per nostril) once daily in the morning during the 12-week Treatment Period.

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the Average Morning (AM) and Evening (PM) Subject-Reported Reflective Total Nasal Symptom Score (rTNSS) Over The First 6 Weeks Of Treatment In Subjects 6 To 11 Years Of Age

    Reflective TNSS is an evaluation of symptom severity over the past 12 hours prior to the recording of the score. Participants (with assistance from parents/guardians/caregivers, as needed) assessed and recorded four nasal symptoms (runny nose, nasal congestion, nasal itching, and sneezing) twice daily (AM and PM) using the following scale: * 0 = absent (no sign/symptom present) * 1 = mild (sign/symptom clearly present, but minimal awareness; easily tolerated) * 2 = moderate (definite awareness of sign/symptom that is bothersome but tolerable) * 3 = severe (sign/symptom that is hard to tolerate; causes interference with activities of daily living and/or sleeping) The total TNSS scale was 0-12 with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms. Baseline and the during study rTNSS values were defined as the average AM and PM subject-reported rTNSS during each time period.

    Time frame: Baseline (Day -4 to Day 1 predose), Day 1 (postdose) to Week 6

Secondary outcomes

  1. Change From Baseline in the Average Morning (AM) and Evening (PM) Subject-Reported Instantaneous Total Nasal Symptom Score (iTNSS) Over The First 6 Weeks Of Treatment In Subjects 6 To 11 Years Of Age

    Instantaneous TNSS is an evaluation of symptom severity over the last 10 minutes prior to the recording of the score. Participants (with assistance from parents/guardians/caregivers, as needed) assessed and recorded four nasal symptoms (runny nose, nasal congestion, nasal itching, and sneezing) twice daily (AM and PM) using the following scale: * 0 = absent (no sign/symptom present) * 1 = mild (sign/symptom clearly present, but minimal awareness; easily tolerated) * 2 = moderate (definite awareness of sign/symptom that is bothersome but tolerable) * 3 = severe (sign/symptom that is hard to tolerate; causes interference with activities of daily living and/or sleeping) The total TNSS scale was 0-12 with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms. Baseline and the during study iTNSS values were defined as the average AM and PM subject-reported iTNSS during each time period.

    Time frame: Baseline (Day -4 to Day 1 predose), Days 1 (postdose) to Week 6

  2. Change From Baseline in the Average Morning (AM) and Evening (PM) Subject-Reported Reflective Total Nasal Symptom Score (rTNSS) Over The First 6 Weeks Of Treatment In Subjects 4 To 11 Years Of Age

    Reflective TNSS is an evaluation of symptom severity over the past 12 hours prior to the recording of the score. Participants (with assistance from parents/guardians/caregivers, as needed) assessed and recorded four nasal symptoms (runny nose, nasal congestion, nasal itching, and sneezing) twice daily (AM and PM) using the following scale: * 0 = absent (no sign/symptom present) * 1 = mild (sign/symptom clearly present, but minimal awareness; easily tolerated) * 2 = moderate (definite awareness of sign/symptom that is bothersome but tolerable) * 3 = severe (sign/symptom that is hard to tolerate; causes interference with activities of daily living and/or sleeping) The total TNSS scale was 0-12 with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms. Baseline and the during study rTNSS values were defined as the average AM and PM subject-reported rTNSS during each time period.

    Time frame: Baseline (Day -4 to Day 1 predose), Day 1 (postdose) to Week 6

  3. Change From Baseline in the Average Morning (AM) and Evening (PM) Subject-Reported Instantaneous Total Nasal Symptom Score (iTNSS) Over The First 6 Weeks Of Treatment In Subjects 4 To 11 Years Of Age

    Instantaneous TNSS is an evaluation of symptom severity over the last 10 minutes prior to the recording of the score. Participants (with assistance from parents/guardians/caregivers, as needed) assessed and recorded four nasal symptoms (runny nose, nasal congestion, nasal itching, and sneezing) twice daily (AM and PM) using the following scale: * 0 = absent (no sign/symptom present) * 1 = mild (sign/symptom clearly present, but minimal awareness; easily tolerated) * 2 = moderate (definite awareness of sign/symptom that is bothersome but tolerable) * 3 = severe (sign/symptom that is hard to tolerate; causes interference with activities of daily living and/or sleeping) The total TNSS scale was 0-12 with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms. Baseline and the during study iTNSS values were defined as the average AM and PM subject-reported iTNSS during each time period.

    Time frame: Baseline (Day -4 to Day 1 predose), Days 1 (postdose) to Week 6

07

Results

Posted Oct 12, 2015

Participant flow

Participant flow — Overall Study
MilestoneBDP Nasal Aerosol 80 mcg/DayPlacebo Nasal Aerosol
Started362185
Full analysis set (fas)358184
Completed328167
Not completed3418
Withdrew: Adverse event84
Withdrew: Withdrawal by subject118
Withdrew: Non-compliance40
Withdrew: Protocol violation22
Withdrew: Lost to follow-up83
Withdrew: Lack of efficacy11

Outcome measures

PrimaryChange From Baseline in the Average Morning (AM) and Evening (PM) Subject-Reported Reflective Total Nasal Symptom Score (rTNSS) Over The First 6 Weeks Of Treatment In Subjects 6 To 11 Years Of Age

Reflective TNSS is an evaluation of symptom severity over the past 12 hours prior to the recording of the score. Participants (with assistance from parents/guardians/caregivers, as needed) assessed and recorded four nasal symptoms (runny nose, nasal congestion, nasal itching, and sneezing) twice daily (AM and PM) using the following scale: * 0 = absent (no sign/symptom present) * 1 = mild (sign/symptom clearly present, but minimal awareness; easily tolerated) * 2 = moderate (definite awareness of sign/symptom that is bothersome but tolerable) * 3 = severe (sign/symptom that is hard to tolerate; causes interference with activities of daily living and/or sleeping) The total TNSS scale was 0-12 with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms. Baseline and the during study rTNSS values were defined as the average AM and PM subject-reported rTNSS during each time period.

Time frame:
Baseline (Day -4 to Day 1 predose), Day 1 (postdose) to Week 6
Reported as:
Least squares mean · units on a scale
Change From Baseline in the Average Morning (AM) and Evening (PM) Subject-Reported Reflective Total Nasal Symptom Score (rTNSS) Over The First 6 Weeks Of Treatment In Subjects 6 To 11 Years Of Age
units on a scaleBDP Nasal Aerosol 80 mcg/DayPlacebo Nasal Aerosol
Change From Baseline in the Average Morning (AM) and Evening (PM) Subject-Reported Reflective Total Nasal Symptom Score (rTNSS) Over The First 6 Weeks Of Treatment In Subjects 6 To 11 Years Of Age-2.26 ± 0.12-1.60 ± 0.17
Statistical analysis
  • BDP Nasal Aerosol 80 mcg/Day vs Placebo Nasal Aerosol · mixed-model for repeated measures (MMRM) · p = 0.002 (a priori statistical significance is \<0.05.) · Lsm treatment difference from placebo: -0.66 · 95% CI -1.08 to -0.24The MMRM included covariate adjustment for baseline, day, treatment, and the treatment by day interaction.
SecondaryChange From Baseline in the Average Morning (AM) and Evening (PM) Subject-Reported Instantaneous Total Nasal Symptom Score (iTNSS) Over The First 6 Weeks Of Treatment In Subjects 6 To 11 Years Of Age

Instantaneous TNSS is an evaluation of symptom severity over the last 10 minutes prior to the recording of the score. Participants (with assistance from parents/guardians/caregivers, as needed) assessed and recorded four nasal symptoms (runny nose, nasal congestion, nasal itching, and sneezing) twice daily (AM and PM) using the following scale: * 0 = absent (no sign/symptom present) * 1 = mild (sign/symptom clearly present, but minimal awareness; easily tolerated) * 2 = moderate (definite awareness of sign/symptom that is bothersome but tolerable) * 3 = severe (sign/symptom that is hard to tolerate; causes interference with activities of daily living and/or sleeping) The total TNSS scale was 0-12 with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms. Baseline and the during study iTNSS values were defined as the average AM and PM subject-reported iTNSS during each time period.

Time frame:
Baseline (Day -4 to Day 1 predose), Days 1 (postdose) to Week 6
Reported as:
Least squares mean · units on a scale
Change From Baseline in the Average Morning (AM) and Evening (PM) Subject-Reported Instantaneous Total Nasal Symptom Score (iTNSS) Over The First 6 Weeks Of Treatment In Subjects 6 To 11 Years Of Age
units on a scaleBDP Nasal Aerosol 80 mcg/DayPlacebo Nasal Aerosol
Change From Baseline in the Average Morning (AM) and Evening (PM) Subject-Reported Instantaneous Total Nasal Symptom Score (iTNSS) Over The First 6 Weeks Of Treatment In Subjects 6 To 11 Years Of Age-1.98 ± 0.12-1.39 ± 0.17
Statistical analysis
  • BDP Nasal Aerosol 80 mcg/Day vs Placebo Nasal Aerosol · mixed-model for repeated measures (MMRM) · p = 0.004 (a priori statistical significance is \<0.05.) · Lsm treatment difference from placebo: -0.58 · 95% CI -0.99 to -0.18The MMRM included covariate adjustment for baseline, day, treatment, and the treatment by day interaction.
SecondaryChange From Baseline in the Average Morning (AM) and Evening (PM) Subject-Reported Reflective Total Nasal Symptom Score (rTNSS) Over The First 6 Weeks Of Treatment In Subjects 4 To 11 Years Of Age

Reflective TNSS is an evaluation of symptom severity over the past 12 hours prior to the recording of the score. Participants (with assistance from parents/guardians/caregivers, as needed) assessed and recorded four nasal symptoms (runny nose, nasal congestion, nasal itching, and sneezing) twice daily (AM and PM) using the following scale: * 0 = absent (no sign/symptom present) * 1 = mild (sign/symptom clearly present, but minimal awareness; easily tolerated) * 2 = moderate (definite awareness of sign/symptom that is bothersome but tolerable) * 3 = severe (sign/symptom that is hard to tolerate; causes interference with activities of daily living and/or sleeping) The total TNSS scale was 0-12 with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms. Baseline and the during study rTNSS values were defined as the average AM and PM subject-reported rTNSS during each time period.

Time frame:
Baseline (Day -4 to Day 1 predose), Day 1 (postdose) to Week 6
Reported as:
Least squares mean · units on a scale
Change From Baseline in the Average Morning (AM) and Evening (PM) Subject-Reported Reflective Total Nasal Symptom Score (rTNSS) Over The First 6 Weeks Of Treatment In Subjects 4 To 11 Years Of Age
units on a scaleBDP Nasal Aerosol 80 mcg/DayPlacebo Nasal Aerosol
Change From Baseline in the Average Morning (AM) and Evening (PM) Subject-Reported Reflective Total Nasal Symptom Score (rTNSS) Over The First 6 Weeks Of Treatment In Subjects 4 To 11 Years Of Age-2.32 ± 0.11-1.71 ± 0.16
Statistical analysis
  • BDP Nasal Aerosol 80 mcg/Day vs Placebo Nasal Aerosol · mixed-model for repeated measures (MMRM) · p = 0.002 (a priori statistical significance is \<0.05.) · Lsm treatment difference from placebo: -0.62 · 95% CI -1.00 to -0.23The MMRM included covariate adjustment for baseline, day, treatment, and the treatment by day interaction.
SecondaryChange From Baseline in the Average Morning (AM) and Evening (PM) Subject-Reported Instantaneous Total Nasal Symptom Score (iTNSS) Over The First 6 Weeks Of Treatment In Subjects 4 To 11 Years Of Age

Instantaneous TNSS is an evaluation of symptom severity over the last 10 minutes prior to the recording of the score. Participants (with assistance from parents/guardians/caregivers, as needed) assessed and recorded four nasal symptoms (runny nose, nasal congestion, nasal itching, and sneezing) twice daily (AM and PM) using the following scale: * 0 = absent (no sign/symptom present) * 1 = mild (sign/symptom clearly present, but minimal awareness; easily tolerated) * 2 = moderate (definite awareness of sign/symptom that is bothersome but tolerable) * 3 = severe (sign/symptom that is hard to tolerate; causes interference with activities of daily living and/or sleeping) The total TNSS scale was 0-12 with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms. Baseline and the during study iTNSS values were defined as the average AM and PM subject-reported iTNSS during each time period.

Time frame:
Baseline (Day -4 to Day 1 predose), Days 1 (postdose) to Week 6
Reported as:
Least squares mean · units on a scale
Change From Baseline in the Average Morning (AM) and Evening (PM) Subject-Reported Instantaneous Total Nasal Symptom Score (iTNSS) Over The First 6 Weeks Of Treatment In Subjects 4 To 11 Years Of Age
units on a scaleBDP Nasal Aerosol 80 mcg/DayPlacebo Nasal Aerosol
Change From Baseline in the Average Morning (AM) and Evening (PM) Subject-Reported Instantaneous Total Nasal Symptom Score (iTNSS) Over The First 6 Weeks Of Treatment In Subjects 4 To 11 Years Of Age-2.07 ± 0.11-1.53 ± 0.15
Statistical analysis
  • BDP Nasal Aerosol 80 mcg/Day vs Placebo Nasal Aerosol · mixed-model for repeated measures (MMRM) · p = 0.004 (a priori statistical significance is \<0.05.) · Lsm treatment difference from placebo: -0.54 · 95% CI -0.91 to -0.17The MMRM included covariate adjustment for baseline, day, treatment, and the treatment by day interaction.

Adverse events

Collected over Day 1 to Week 16. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BDP Nasal Aerosol 80 mcg/Day—0/362 (0%)33/362 (9.1%)
Placebo Nasal Aerosol—0/185 (0%)21/185 (11.4%)
Most frequent other events
Most frequent other events
EventBDP Nasal Aerosol 80 mcg/DayPlacebo Nasal Aerosol
HeadacheNervous system disorders16/36214/185
EpistaxisRespiratory, thoracic and mediastinal disorders18/3628/185

Baseline characteristics

Intent to treat population which included all randomized participants.

Age, Continuous
Age, Continuous(years)BDP Nasal Aerosol 80 mcg/DayPlacebo Nasal AerosolTotal
Mean8.0 ± 2.168.0 ± 2.238.0 ± 2.18
Age, Customized
Age, Customized(participants)BDP Nasal Aerosol 80 mcg/DayPlacebo Nasal AerosolTotal
4 to 5 years623193
6 to 11 years300154454
Sex: Female, Male
Sex: Female, Male(Participants)BDP Nasal Aerosol 80 mcg/DayPlacebo Nasal AerosolTotal
Female17571246
Male187114301
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)BDP Nasal Aerosol 80 mcg/DayPlacebo Nasal AerosolTotal
White272145417
Black652590
Other251540
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)BDP Nasal Aerosol 80 mcg/DayPlacebo Nasal AerosolTotal
Hispanic or Latino14475219
Not Hispanic or Latino217110327
Unknown101
Weight
Weight(kg)BDP Nasal Aerosol 80 mcg/DayPlacebo Nasal AerosolTotal
Mean33.4 ± 13.4033.8 ± 13.2433.5 ± 13.34
Body Mass Index
Body Mass Index(kg/m^2)BDP Nasal Aerosol 80 mcg/DayPlacebo Nasal AerosolTotal
Mean18.6 ± 4.2218.9 ± 4.3318.7 ± 4.25
08

Study locations

63 sites
  • Teva Investigational Site 10522
    Hot Springs, Arkansas, United States
  • Teva Investigational Site 10518
    Costa Mesa, California, United States
  • Teva Investigational Site 10526
    Downey, California, United States
  • Teva Investigational Site 10496
    Huntington Beach, California, United States
  • Teva Investigational Site 10536
    Huntington Beach, California, United States
  • Teva Investigational Site 10479
    Mission Viejo, California, United States
  • Teva Investigational Site 10524
    Orange, California, United States
  • Teva Investigational Site 10508
    Paramount, California, United States
  • Teva Investigational Site 10495
    San Diego, California, United States
  • Teva Investigational Site 10504
    San Diego, California, United States
  • Teva Investigational Site 10505
    Stockton, California, United States
  • Teva Investigational Site 10514
    Centennial, Colorado, United States
  • Teva Investigational Site 10503
    Colorado Springs, Colorado, United States
  • Teva Investigational Site 10499
    Lawrenceville, Georgia, United States
  • Teva Investigational Site 10474
    Savannah, Georgia, United States
  • Teva Investigational Site 10490
    Stockbridge, Georgia, United States
  • Teva Investigational Site 10498
    Stockbridge, Georgia, United States
  • Teva Investigational Site 10509
    Dekalb, Illinois, United States
  • Teva Investigational Site 10493
    Normal, Illinois, United States
  • Teva Investigational Site 10486
    Indianapolis, Indiana, United States
  • Teva Investigational Site 10494
    Louisville, Kentucky, United States
  • Teva Investigational Site 10515
    North Dartmouth, Massachusetts, United States
  • Teva Investigational Site 10540
    Traverse City, Michigan, United States
  • Teva Investigational Site 10513
    Columbia, Missouri, United States
  • Teva Investigational Site 10532
    Missoula, Montana, United States
  • Teva Investigational Site 10507
    Brick, New Jersey, United States
  • Teva Investigational Site 10534
    Corning, New York, United States
  • Teva Investigational Site 10492
    Cortland, New York, United States
  • Teva Investigational Site 10517
    Niagara Falls, New York, United States
  • Teva Investigational Site 10482
    Rochester, New York, United States
  • Teva Investigational Site 10535
    Watertown, New York, United States
  • Teva Investigational Site 10478
    High Point, North Carolina, United States
  • Teva Investigational Site 10516
    Holly Springs, North Carolina, United States
  • Teva Investigational Site 10485
    Canton, Ohio, United States
  • Teva Investigational Site 10480
    Cincinnati, Ohio, United States
  • Teva Investigational Site 10500
    Cleveland, Ohio, United States
  • Teva Investigational Site 10529
    Middleburg Heights, Ohio, United States
  • Teva Investigational Site 10537
    Ashland, Oregon, United States
  • Teva Investigational Site 10527
    Medford, Oregon, United States
  • Teva Investigational Site 10502
    Portland, Oregon, United States
  • Teva Investigational Site 10477
    Blue Bell, Pennsylvania, United States
  • Teva Investigational Site 10484
    Upland, Pennsylvania, United States
  • Teva Investigational Site 10511
    Warwick, Rhode Island, United States
  • Teva Investigational Site 10497
    Charleston, South Carolina, United States
  • Teva Investigational Site 10521
    Orangeburg, South Carolina, United States
  • Teva Investigational Site 10528
    Knoxville, Tennessee, United States
  • Teva Investigational Site 10483
    Boerne, Texas, United States
  • Teva Investigational Site 10489
    Dallas, Texas, United States
  • Teva Investigational Site 10520
    Dallas, Texas, United States
  • Teva Investigational Site 10476
    El Paso, Texas, United States
  • Teva Investigational Site 10491
    Kerrville, Texas, United States
  • Teva Investigational Site 10487
    Plano, Texas, United States
  • Teva Investigational Site 10501
    Plano, Texas, United States
  • Teva Investigational Site 10523
    San Antonio, Texas, United States
  • Teva Investigational Site 10531
    San Antonio, Texas, United States
  • Teva Investigational Site 10539
    San Antonio, Texas, United States
  • Teva Investigational Site 10475
    Waco, Texas, United States
  • Teva Investigational Site 10488
    Salt Lake City, Utah, United States
  • Teva Investigational Site 10506
    Salt Lake City, Utah, United States
  • Teva Investigational Site 10510
    Salt Lake City, Utah, United States
  • Teva Investigational Site 10519
    Burke, Virginia, United States
  • Teva Investigational Site 10481
    Richmond, Virginia, United States
  • Teva Investigational Site 10533
    Richmond, Virginia, United States
09

References and documents

Publications

  • Berger WE, Jacobs RL, Amar NJ, Tantry SK, Li J, Small CJ. Efficacy and safety of beclomethasone dipropionate nasal aerosol in children with perennial allergic rhinitis. Ann Allergy Asthma Immunol. 2015 Aug;115(2):130-6. doi: 10.1016/j.anai.2015.05.012. Epub 2015 Jun 24. PubMed 26115578 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2013, a primary completion of Oct 2013 and a completion of Oct 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2015, 2 years after primary completion. A results delay was requested in May 2014.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 31, 2013
First posted
Feb 5, 2013
Start
Jan 2013
Primary completionActual
Oct 2013
CompletionActual
Oct 2013
Results delay requested
May 8, 2014
Results first posted
Oct 12, 2015
Last update
Oct 12, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 12, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01783548
Responsible party
Sponsor
First posted
Feb 5, 2013
Start date
Jan 2013
Primary completion
Oct 2013
Completion
Oct 2013
Results posted
Oct 12, 2015
Last update
Oct 12, 2015

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Beclomethasone

Start the discussion